Modality
Degrader
MOA
IL-23i
Target
SGLT2
Pathway
Sphingolipid
GATTR Amyloidosis
Development Pipeline
Preclinical
~Dec 2020
→ ~Mar 2022
Phase 1
~Jun 2022
→ ~Sep 2023
Phase 2
Dec 2023
→ Nov 2027
Phase 2Current
NCT05761209
2,911 pts·TTR Amyloidosis
2023-12→2027-11·Not yet recruiting
2,911 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-11-171.6y awayPh2 Data· TTR Amyloidosis
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P2
Not yet…
Catalysts
Ph2 Data
2027-11-17 · 1.6y away
TTR Amyloidosis
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05761209 | Phase 2 | TTR Amyloidosis | Not yet recr... | 2911 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| Zenotapinarof | Vertex Pharma | Preclinical | CD38 | |
| SRP-3270 | Sarepta | Phase 1/2 | SGLT2 | |
| Tirarapivir | United Therapeutics | Approved | SGLT2 | |
| Bemasotorasib | Exelixis | Phase 2 | CD38 |